Literature DB >> 25100535

Caffeic acid phenethyl ester: its protective role against certain major eye diseases.

Sumeyya Akyol1, Veli Ugurcu, Mehmet Balci, Ayse Gurel, Gonul Erden, Ozlem Cakmak, Omer Akyol.   

Abstract

As an effective compound found mainly in the honeybee product propolis, caffeic acid phenethyl ester (CAPE) has been commonly utilized as a medicine and remedial agent, in a number of countries. Specifically, it might inhibit nuclear factor kappa B at micromolar concentrations and demonstrate antioxidant, antineoplastic, antiproliferative, cytostatic, antiviral, antibacterial, antifungal, and anti-inflammatory features. This review article summarizes the recent progress regarding the favorable effects of CAPE on a number of eye disease models, including cataract and posterior capsule opacification, corneal diseases, retina and optic nerve-related diseases, ischemia/reperfusion injury of retina, inflammation and infection-related diseases. CAPE has been found to exhibit promising efficacy, with minimal adverse effects, in animal and cell culture studies of several eye diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25100535     DOI: 10.1089/jop.2014.0046

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  3 in total

Review 1.  Recent progresses in the pharmacological activities of caffeic acid phenethyl ester.

Authors:  Lili Lv; Honghua Cui; Zhiming Ma; Xin Liu; Longfei Yang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-01-25       Impact factor: 3.000

2.  Current and Future Techniques in Wound Healing Modulation after Glaucoma Filtering Surgeries.

Authors:  Masoumeh B Masoumpour; M Hossein Nowroozzadeh; M Reza Razeghinejad
Journal:  Open Ophthalmol J       Date:  2016-02-29

3.  Caffeic acid phenethyl ester attenuates nuclear factor‑κB‑mediated inflammatory responses in Müller cells and protects against retinal ganglion cell death.

Authors:  Yanwen Jia; Shengqun Jiang; Chen Chen; Guohua Lu; Yang Xie; Xincheng Sun; Liqin Huang
Journal:  Mol Med Rep       Date:  2019-04-11       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.